XDx Selects Ingenuity Systems IPA 5.0 for Pathways Solution

REDWOOD CITY, California, July 10 /PRNewswire/ --

- New IPA-Biomarker(TM) Capability Critical for Expression Diagnostics
Discovery and Development

Ingenuity Systems, the leading provider of solutions to explore, analyze,
and interpret scientific literature and data, today announced that XDx, a
leading molecular diagnostics company, has licensed Ingenuity's flagship
solution IPA 5.0. Ingenuity Systems was selected by XDx after a comprehensive
evaluation of several pathway analysis products.

Founded in 2000, XDx is a molecular diagnostics company based in
Brisbane, California. Setting the stage for a new era in personalized
medicine, XDx is one of the first companies to develop and commercialize
practical applications built on insights from the Human Genome Project. The
company has developed a proprietary new method for noninvasively monitoring
the immune system by measuring gene expression in a patient's peripheral
blood. The technology offers the potential to decrease healthcare costs and
significantly improve the quality of life for patients with a variety of
life-threatening or life-altering immune-mediated diseases.

"We chose IPA because it best meets our objective to identify and
understand biomarkers associated with immune-mediated diseases," commented
Dr. Tod Klingler, VP of Informatics at XDx. "IPA provides us with access to
its extensive knowledge base of gene function information assembled from the
scientific literature through easy-to-use tools that our researchers can use
to rapidly evaluate candidate biomarkers. Specifically, IPA allows us to make
sense of our gene expression data in the context of known immune system
interactions and pathways."

"We are very pleased to have been selected by XDx as an important tool in
their research programs," stated Peter DiLaura, Senior Vice President,
Commercial Operations at Ingenuity Systems. "As with many of our customers
involved in biomarker research, IPA is well-suited for XDx because the
expansive, expert-extracted scientific content can be applied in their
initial exploratory research, and then tools in IPA, such as IPA-Biomarker(TM), 
can be used to identify or compare their biomarker candidates. IPA 5.0 enables 
them to apply filters to their data to determine whether a particular gene or 
protein is detectable in sentinel tissues or other bodily fluids, so potential
candidates are identified much more effectively than in traditional 
approaches."

Ingenuity Pathways Analysis is a software application that enables
researchers to model, analyze, and understand the complex biological and
chemical systems at the core of life science research. IPA is deployed in all
major pharmaceutical companies and in hundreds of biotechnology companies and
academic institutions globally. It supports analysis of data from all
experimental platforms, and is used at all stages of the drug discovery and
development process, including target identification and validation,
identification of biomarkers, predictive toxicology, and pharmacogenomics.

Trials of Ingenuity Pathways Analysis 5.0 are currently being offered at
http://www.ingenuity.com/trial. For more information about Ingenuity
Pathways Analysis, please email sales@ingenuity.com or go to
http://www.ingenuity.com

About Ingenuity Systems(R)

Ingenuity enables researchers to model, analyze, and understand complex
biological and chemical systems foundational to human health and disease. The
Ingenuity products include pathways analysis software and knowledge bases for
life scientists and bioinformaticians, and enterprise knowledge management
infrastructure, content and services for leading pharmaceutical and biotech
companies. Ingenuity was founded in 1998 and is headquartered in Redwood
City, California with offices in Germany, Switzerland, France, the United
Kingdom, and Japan. http://www.ingenuity.com.

About XDx

XDx's mission is to improve patient care by developing molecular
diagnostics that translate an individual's immune status into clinically
actionable information.

XDx is a molecular diagnostics company that utilizes state-of-the-art
genomic technology and sophisticated bioinformatics analyses to understand
and measure the immune processes that underlie specific immune-mediated
conditions. Physicians can use this information to optimize patient treatment
and minimize the long-term consequences of immunosuppressive therapies.

XDx's science and technology is now being evaluated in patients with
solid organ transplants. Building on the discoveries made during the
development of AlloMap(R) testing for heart transplant patients, which
included the identification of many genes and pathways involved in tissue
rejection, XDx is now developing a product for use by physicians to better
manage lung transplant patients.

Beyond the use of AlloMap testing in assessing immune response in solid
organ transplantation, XDx scientists are applying similar approaches to
create new molecular diagnostic tests for the improved clinical management of
immune-mediated inflammatory diseases, such as systemic lupus erythematosus
(SLE or lupus), to diagnose and predict clinical flares common in a variety
of these diseases.

Web site: http://www.ingenuity.com